临床试验参与与复发性铂耐药卵巢癌总生存改善的关联
该回顾性单机构队列研究纳入2009年1月1日至2017年12月31日305例铂耐药卵巢癌患者,其中46例(15.1%)参与临床试验。多因素分析显示,参与临床试验与从铂耐药之日起总生存显著改善相关(13.8个月 vs 10.5个月,校正风险比1.46,95%CI 1.04-2.05,P=.028)。
要点
- 在305例铂耐药卵巢癌患者中,46例(15.1%)参与了临床试验。
- 临床试验参与组从铂耐药起总生存为13.8个月,标准治疗组为10.5个月(校正HR 1.46,95%CI 1.04-2.05,P=.028)。
- 作者建议在复发性铂耐药卵巢癌患者中优先考虑临床试验的可及性与参与。
核心结论
- 在这项铂耐药卵巢癌回顾性队列中,参与临床试验与标准治疗相比与总生存改善相关。
- 作者建议在复发性铂耐药卵巢癌患者中优先考虑临床试验的可及性与参与。
研究设计与样本
- 经IRB批准的回顾性单机构队列研究,纳入2009年1月1日至2017年12月31日铂耐药卵巢癌患者。
- 铂耐药定义为完成铂类化疗后6个月内进展。
- 患者分为临床试验参与组(针对铂耐药卵巢癌的试验)与标准治疗组,共305例 eligible 患者,其中46例(15.1%)为临床试验参与者。
主要发现
- 临床试验参与组与标准治疗组在年龄(61.2岁 vs 63.3岁,P=.21)、体重指数(27.5 vs 27.6,P=.90)、种族(P=.61)、合并症(P>.05)和体能状态(P=.07)方面无显著差异。
- 两组接受初次肿瘤细胞减灭术的比例分别为76.1% vs 69.1%(P=.34),残留病灶无差异(P=.43)。
- 两组聚ADP核糖聚合酶抑制剂使用(21.7% vs 15.1%,P=.26)和贝伐珠单抗使用(22.2% vs 32.1%,P=.31)无差异。
- 控制合并症、分期和胚系突变状态后,临床试验参与与从铂耐药之日起总生存显著改善相关(13.8个月 vs 10.5个月,校正风险比1.46,95%CI 1.04-2.05,P=.028)。
临床怎么用
- 原文结论指出,对于复发性铂耐药卵巢癌患者,应优先考虑临床试验的可及性与参与(作者建议)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether clinical trial participation is associated with overall survival in patients with platinum-resistant ovarian cancer. METHODS: An IRB-approved, retrospective, single-institution cohort study was performed in patients with platinum-resistant ovarian cancer from January 1, 2009, to December 31, 2017. Platinum resistance was defined as progression within 6 months after completion of platinum chemotherapy. Patients were divided into two cohorts: 1) clinical trial participants for platinum-resistant ovarian cancer or 2) standard of care. The association of trial participation with overall survival from the date of platinum resistance was assessed with univariate and multivariable models. RESULTS: Of 305 eligible patients with recurrent platinum-resistant ovarian cancer, 46 (15.1%) were clinical trial participants. There were no significant differences in age (61.2 years vs 63.3 years, P =.21), body mass index (27.5 vs 27.6, P =.90), race ( P =.61), medical comorbidities ( P >.05), or performance status ( P =.07) for clinical trial participants compared with those receiving standard of care. The majority underwent primary cytoreduction (76.1% vs 69.1%, P =.34) with no differences in residual disease ( P =.43) for clinical trial participants compared with those receiving standard of care. There was no difference in poly-ADP-ribose polymerase inhibitor (21.7% vs 15.1%, P =.26) or bevacizumab (22.2% vs 32.1%, P =.31) use for clinical trial participants compared with those receiving standard of care. On multivariable analysis controlling for comorbidities, stage, and germline mutational status, clinical trial participation was associated with significantly improved overall survival from the date of platinum resistance compared with standard of care (13.8 months vs 10.5 months, adjusted hazard ratio 1.46, 95% CI 1.04-2.05, P =.028). CONCLUSIONS: In this retrospective cohort of patients with platinum-resistant ovarian cancer, clinical trial participation was associated with improved overall survival compared with standard of care therapies. Availability and participation in clinical trials should be prioritized in patients with recurrent, platinum-resistant ovarian cancer.
引用
- Morton M, Yao M, Chalif J, et al. Association of Clinical Trial Participation With Improved Overall Survival for Recurrent, Platinum-Resistant Ovarian Cancer. Obstet Gynecol. 2023. PMID: 37535957. doi:10.1097/AOG.0000000000005298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。